BACKGROUND: Systemic treatment with immune combinations is the gold standard for metastatic renal cell carcinoma (mRCC) worldwide. The systemic immune-inflammation index (SII) is a prognostic marker for several types of malignant neoplasms, including mRCC, in the era of tyrosine kinase inhibitor (TKI) treatment. Data regarding the prognostic value of the SII in patients with mRCC treated with immunotherapy are scarce and controversial. METHODS: We retrospectively collected the data of patients with mRCC from 56 centers in 18 countries. SII (Platelet × Neutrophil/Lymphocyte count) was calculated prior to the first systemic treatment and cut-off was defined by a survival receiver operating characteristic (ROC) analysis. The primary objective of our retrospective study was to assess the outcomes of patients treated with first-line immunotherapy. RESULTS: Data from 1034 mRCC patients was collected and included in this analysis. The SII cut-off value was 1265. After a follow-up of 26.7 months, and the overall survival (OS) and progression-free survival (PFS) were 39.8 and 15.7 months, respectively. According to SII (low vs. high), patients with low-SII had longer OS (55.7 vs. 22.2 months, P < .001), better PFS (20.8 vs. 8.5 months, P < .001), and higher overall response rate (52 vs. 37%, P = .033). CONCLUSION: A high SII is associated with poor oncological outcomes in patients with mRCC. SII could be an easily accessible prognostic indicator for use in clinical practice.

2nd Propaedeutic Department of Internal Medicine ATTIKON University Hospital National and Kapodistrian University of Athens School of Medicine Athens Greece

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Biomedical Sciences and Human Oncology University of Bari Aldo Moro Bari Italy

Department of Clinical Oncology and Radiotherapy University Hospital Hradec Kralove Hradec Kralove Czechia

Department of Medical Oncology Army Hospital Research and Referral New Delhi India

Department of Medical Oncology Centre Hospitalier de Jolimont Haine Saint Paul Belgium

Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain

Department of Medical Oncology University Hospital Ramón y Cajal Madrid Spain

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital Prague Czech Republic

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital Charles University Pilsen Czech Republic

Department of Uro oncology Maria Sklodowska Curie National Research Institute of Oncology Warsaw Warsaw Poland

Department of Urology Medical University of Innsbruck Innsbruck Austria

Department of Urology University Hospital Bonn 53127 Bonn Germany

Hematology and Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

Hospital Sirio Libanês Brasilia DF Brazil

Latin American Cooperative Oncology Group LACOG Porto Alegre RS Brazil

Markey Cancer Center University of Kentucky Lexington KY

Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia

Medical Oncology Tawam Hospital Al Ain United Arab Emirates

Oncology Unit Macerata Hospital Macerata Italy

PUCRS School of Medicine Porto Alegre RS Brazil

Urologic Oncology Champalimaud Clinical Center Lisbon Portugal

000      

00000naa a2200000 a 4500

001      

bmc24006606

003      

CZ-PrNML

005      

20240423155406.0

007      

ta

008      

240412s2024 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.clgc.2023.11.013 $2 doi

035    __

$a (PubMed)38087702

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Monteiro, Fernando Sabino Marques $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil; Hospital Sirio Libanês, Brasilia, DF, Brazil; PUCRS School of Medicine, Porto Alegre, RS, Brazil. Electronic address: fsabinocba@gmail.com

245    10

$a Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study / $c FSM. Monteiro, O. Fiala, F. Massari, ZW. Myint, J. Kopecky, J. Kucharz, T. Büttner, E. Grande, MT. Bourlon, J. Molina-Cerrillo, R. Pichler, T. Buchler, E. Seront, J. Ansari, A. Bamias, D. Bhuva, N. Vau, C. Porta, AP. Fay, M. Santoni

520    9_

$a BACKGROUND: Systemic treatment with immune combinations is the gold standard for metastatic renal cell carcinoma (mRCC) worldwide. The systemic immune-inflammation index (SII) is a prognostic marker for several types of malignant neoplasms, including mRCC, in the era of tyrosine kinase inhibitor (TKI) treatment. Data regarding the prognostic value of the SII in patients with mRCC treated with immunotherapy are scarce and controversial. METHODS: We retrospectively collected the data of patients with mRCC from 56 centers in 18 countries. SII (Platelet × Neutrophil/Lymphocyte count) was calculated prior to the first systemic treatment and cut-off was defined by a survival receiver operating characteristic (ROC) analysis. The primary objective of our retrospective study was to assess the outcomes of patients treated with first-line immunotherapy. RESULTS: Data from 1034 mRCC patients was collected and included in this analysis. The SII cut-off value was 1265. After a follow-up of 26.7 months, and the overall survival (OS) and progression-free survival (PFS) were 39.8 and 15.7 months, respectively. According to SII (low vs. high), patients with low-SII had longer OS (55.7 vs. 22.2 months, P < .001), better PFS (20.8 vs. 8.5 months, P < .001), and higher overall response rate (52 vs. 37%, P = .033). CONCLUSION: A high SII is associated with poor oncological outcomes in patients with mRCC. SII could be an easily accessible prognostic indicator for use in clinical practice.

650    _2

$a lidé $7 D006801

650    12

$a karcinom z renálních buněk $x patologie $7 D002292

650    _2

$a retrospektivní studie $7 D012189

650    12

$a nádory ledvin $x patologie $7 D007680

650    _2

$a analýza přežití $7 D016019

650    _2

$a prognóza $7 D011379

650    _2

$a zánět $x patologie $7 D007249

655    _2

$a časopisecké články $7 D016428

700    1_

$a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

700    1_

$a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia

700    1_

$a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY

700    1_

$a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia

700    1_

$a Kucharz, Jakub $u Department of Uro-oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland

700    1_

$a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany

700    1_

$a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain

700    1_

$a Bourlon, Maria Teresa $u Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

700    1_

$a Molina-Cerrillo, Javier $u Department of Medical Oncology, University Hospital Ramón y Cajal, Madrid, Spain

700    1_

$a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria

700    1_

$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic

700    1_

$a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium

700    1_

$a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates

700    1_

$a Bamias, Aristotelis $u 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

700    1_

$a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India

700    1_

$a Vau, Nuno $u Urologic Oncology, Champalimaud Clinical Center, Lisbon, Portugal

700    1_

$a Porta, Camillo $u Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy

700    1_

$a Fay, Andre Poisl $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil; PUCRS School of Medicine, Porto Alegre, RS, Brazil

700    1_

$a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy

773    0_

$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 22, č. 2 (2024), s. 305-314.e3

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38087702 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423155403 $b ABA008

999    __

$a ok $b bmc $g 2080921 $s 1216373

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 22 $c 2 $d 305-314.e3 $e 20231124 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741

LZP    __

$a Pubmed-20240412